Electrophysiology

The cardiac subspecialty of electrophysiology (EP) diagnoses and treats arrhythmias. This includes use of pacemakers to treat bradycardia, implantable cardioverter defibrillators (ICD) for tachycardia, heart failure and patients at risk of sudden cardiac arrest, and cardiac ablation treatments to treat heart rhythm disorders.

The Medtronic SelectSecure MRI SureScan Model 3830 cardiac lead already gained FDA approval for His-Bundle pacing back in 2018. Now, the lead is also approved for left bundle branch area pacing, providing users with another option when treating patients for bradycardia. According to Medtronic, this marks the first time the FDA has approved a device for this indication.

Medtronic cardiac lead the first to receive FDA approval for conduction system pacing

The company’s SelectSecure MRI SureScan Model 3830 cardiac lead already gained FDA approval for His-Bundle pacing back in 2018. Now, the lead is also approved for left bundle branch area pacing.

CT has been used for planning and procedural guidance in pulmonary vein isolation (PVI) for about 20 years. It shows the anatomy to the electrophysiologist. The EPs also can load the imaging into their EP mapping system. It also shows them the location of the esophagus and the phrenic nerve so they can avoid these during the procedures. #PVI #EPeeps

VIDEO: The expanding role of cardiac CT in electrophysiology

Harold Litt, MD, division chief of cardiothoracic imaging and director of the Center for Advanced CT Imaging Sciences at the Perelman School of Medicine of the University of Pennsylvania, explains the role of cardiac CT in EP procedures.

A FEOPS image of a Watchman LAA occluder device being checked for virtual sizing in an anatomical model of the patient's left atrial appendage. Dhanunjaya Lakkireddy, MD, explains the role and technology of LAA closure devices in managing AFib patients.

VIDEO: The value of left atrial appendage occlusion in AFib patients

Dhanunjaya Lakkireddy, MD, executive medical director for the Kansas City Heart Rhythm Institute at HCA Midwest Health, explains recent trials in left atrial appendage occlusion (LAAO) and how the therapy helps atrial fibrillation (AFib) patients. 

Thumbnail

Researchers awarded $37M to see if Apple Watch can lower stroke risk among AFib patients

Could wearables help AFib patients take fewer blood-thinning medications and reduce their risk of stroke? The team behind a new seven-year analysis hopes to find out. 

Dhanunjaya "DJ" Lakkireddy, MD, executive medical director for the Kansas City Heart Rhythm Institute at HCA Midwest Health, professor of medicine at the University of Missouri, Columbia, deputy editor for the the Journal of Atrial Fibrillation, and serves on the HRS Board of Trustees and section steering committee chair for the ACC, explains the potentially devastating impact of Medicare cuts on electrophysiology (EP) and patient care.

VIDEO: Medicare cuts could devastate the field of electrophysiology

"By imposing a 35%-42% cut, [CMS] has essentially created a scenario where it is going to destroy electrophysiology as a field," explained Dhanunjaya "DJ" Lakkireddy, MD.

The U.S. Food and Drug Administration (FDA) has granted the first pediatric indication for use for an implantable cardiac monitor to Medtronic. The Linq II Insertable Cardiac Monitor (ICM) system is the first such device receive 510(k) clearance for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.

FDA grants new pediatric indication for Medtronic Linq II implantable cardiac monitor 

The FDA granted the first pediatric indication for an implantable cardiac monitor. The Linq II can be used in pediatric patients over the age of 2 for up to 4.5 years of long-term, continuous monitoring. 

Thumbnail

1 in 20 hospitalized COVID-19 patients develop new-onset AFib

Researchers examined data from nearly 31,000 adult patients hospitalized with COVID-19, sharing their findings in Circulation: Arrhythmia and Electrophysiology.

Thermedical SERF thermal ablation system for VT.

FDA approves trial for new type of thermal-ablation system to treat ventricular arrhythmias

The FDA has approved a clinical trial to evaluate the safety and efficacy of a new type of ablation catheter for patients with ventricular tachycardia (VT) resistant to conventional anti-arrhythmic drugs or standard ablation procedures.